Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC

References

• Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic non-small-cell Lung Cancer: A Review. JAMA 322(8), 764–774 (2019).
   PubMed Web of Science ®Google Scholar
• Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. Lancet 401(10374), 390–408 (2023).
   PubMed Web of Science ®Google Scholar
• Westeel V, Foucher P, Scherpereel A et al. Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 23(9), 1180–1188 (2022).
   PubMed Web of Science ®Google Scholar
• de Koning HJ, van der Aalst CM, de Jong PA et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N. Engl. J. Med. 382(6), 503–513 (2020).
   PubMed Web of Science ®Google Scholar
• Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365(5), 395–409 (2011).
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang Y, Fang M. Analysis of tumor markers in pleural effusion and serum to verify the correlations between serum tumor markers and tumor size, TNM stage of lung adenocarcinoma. Cancer Med. 9(4), 1392–1399 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang M, Yan L, Lippi G, Hu ZD. Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review. Transl. Lung Cancer Res. 10(3), 1557–1570 (2021).
   PubMed Web of Science ®Google Scholar
• Luo H, Wei W, Ye Z, Zheng J, Xu RH. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends Mol. Med. 27(5), 482–500 (2021).
   PubMed Web of Science ®Google Scholar
• Jamshidi A, Liu MC, Klein EA et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 40(12), 1537–1549 (2022).
   PubMed Web of Science ®Google Scholar
• Song P, Wu LR, Yan YH et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat. Biomed. Eng. 6(3), 232–245 (2022).
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J. Hematol. Oncol. 15(1), 131 (2022).
   PubMed Web of Science ®Google Scholar
• Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17(1), 89–97 (1998).
   PubMed Web of Science ®Google Scholar
• Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell 164(1–2), 57–68 (2016).
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659–1665 (2001).
   PubMed Web of Science ®Google Scholar
• Mehra N, Dolling D, Sumanasuriya S et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur. Urol. 74(3), 283–291 (2018).
   PubMed Web of Science ®Google Scholar
• Yeh YM, Lin PC, Lee CT et al. Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA. Mol. Cancer 19(1), 150 (2020).
   PubMed Web of Science ®Google Scholar
• Yu D, Tong Y, Guo X et al. Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis. Front Oncol. 9, 95 (2019).
   PubMed Web of Science ®Google Scholar
• Szpechcinski A, Rudzinski P, Kupis W, Langfort R, Orlowski T, Chorostowska-Wynimko J. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Lett. 374(2), 202–207 (2016).
   PubMed Web of Science ®Google Scholar
• Kumar S, Nadda N, Paul S et al. Evaluation of the cell-free DNA integrity index as a liquid biopsy marker to differentiate hepatocellular carcinoma from chronic liver disease. Front Mol. Biosci. 9, 1024193 (2022).
   PubMed Web of Science ®Google Scholar
• Vizza E, Corrado G, De Angeli M et al. Serum DNA integrity index as a potential molecular biomarker in endometrial cancer. J. Exp. Clin. Cancer Res. 37(1), 16 (2018).
   PubMedGoogle Scholar
• Salvianti F, Giuliani C, Petrone L et al. Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological Classification. Int. J. Mol. Sci. 18(7), 1350 (2017).
   PubMed Web of Science ®Google Scholar
• Zhu F, Ma J, Ru D et al. Plasma DNA Integrity as a Prognostic Biomarker for Colorectal Cancer Chemotherapy. J. Oncol. 2021, 5569783 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang R, Pu W, Zhang S et al. Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: a retrospective cohort trial. PLOS ONE 13(2), e0191756 (2018).
   PubMed Web of Science ®Google Scholar
• Liu B, Ricarte Filho J, Mallisetty A et al. Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of non-small-cell Lung Cancer. Clin. Cancer Res. 26(16), 4339–4348 (2020).
   PubMed Web of Science ®Google Scholar
• Janke F, Angeles AK, Riediger AL et al. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small-cell lung cancer patients. Clin. Epigenetics 14(1), 163 (2022).
   PubMed Web of Science ®Google Scholar
• Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular Epidemiology of the Main Druggable Genetic Alterations in non-small-cell Lung Cancer. Int. J. Mol. Sci. 22(2), 612 (2021).
   PubMed Web of Science ®Google Scholar
• Heitzer E, van den Broek D, Denis MG et al. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open 7(2), 100399 (2022).
   PubMed Web of Science ®Google Scholar
• Pinter TBJ, Ruckthong L, Stuckey JA, Deb A, Penner-Hahn JE, Pecoraro VL. Open Reading Frame 1 Protein of the Human Long Interspersed Nuclear Element 1 Retrotransposon Binds Multiple Equivalents of Lead. J. Am. Chem. Soc. 143(37), 15271–15278 (2021).
   PubMed Web of Science ®Google Scholar
• Zhitnyuk YV, Koval AP, Alferov AA et al. Deep cfDNA fragment end profiling enables cancer detection. Mol. Cancer 21(1), 26 (2022).
   PubMed Web of Science ®Google Scholar
• An Y, Zhao X, Zhang Z et al. DNA methylation analysis explores the molecular basis of plasma cell-free DNA fragmentation. Nat. Commun. 14(1), 287 (2023).
   PubMed Web of Science ®Google Scholar
• Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA – looking beyond the blood. Nat. Rev. Clin. Oncol. 19(9), 600–612 (2022).
   PubMed Web of Science ®Google Scholar
• Leng S, Zheng J, Jin Y et al. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small-cell lung cancer from tuberculosis. Clin. Chim. Acta 477, 160–165 (2018).
   PubMed Web of Science ®Google Scholar
• Jylhävä J, Kotipelto T, Raitala A, Jylhä M, Hervonen A, Hurme M. Aging is associated with quantitative and qualitative changes in circulating cell-free DNA: the Vitality 90+ study. Mech. Ageing Dev. 132(1–2), 20–26 (2011).
   PubMed Web of Science ®Google Scholar
• Sozzi G, Conte D, Leon M et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J. Clin. Oncol. 21(21), 3902–3908 (2003).
   PubMed Web of Science ®Google Scholar
• Huang A, Zhang X, Zhou SL et al. Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma. J. Cancer 7(13), 1798–1803 (2016).
   PubMed Web of Science ®Google Scholar
• Madhavan D, Wallwiener M, Bents K et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis. Breast Cancer Res. Treat. 146(1), 163–174 (2014).
   PubMed Web of Science ®Google Scholar
• Ren S, Ren XD, Guo LF et al. Urine cell-free DNA as a promising biomarker for early detection of non-small-cell lung cancer. J. Clin. Lab. Anal. 34(8), e23321 (2020).
   PubMed Web of Science ®Google Scholar
• Ren S, Ren X, Guo H et al. Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis. Per. Med. 18(2), 129–139 (2021).
   PubMed Web of Science ®Google Scholar
• Soliman SE, Alhanafy AM, Habib MSE, Hagag M, Ibrahem RAL. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem. Biophys Rep. 15, 45–51 (2018).
   PubMedGoogle Scholar